Set Your Location to See Relevant Information

Breast Cancer: S1418/BR006

Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer (S1418/BR006)

Objective

The purpose of this study is to compare the usual approach (i.e. no more treatment or additional post-operative chemotherapy), to any effects, good and/or bad, of the experimental drug MK-3475 (also called pembrolizumab) after surgery.

This study will allow the researchers to know whether treatment with MK-3475 (pembrolizumab) is better, the same, or worse than the usual approach. There will be about 1,000 people taking part in this study across all research sites.

For more information please visit the National Cancer Institute.

LOCATIONS:

1. Genesis Cancer Care Institute

1401 W. Central Park Ave.

Davenport, IA 52804

Phone Number: 563-421-1900

2. Genesis Cancer Clinic-Silvis

801 Illini Dr.

Silvis, IL 61282

Phone Number: 563-421-1900

3. Iowa Cancer Specialists

1750 E. 53rd St.

Davenport, IA 52807

Phone Number: 563-345-4325

Clinical Trial Categories

• Breast Cancer

Sponsor(s)

SWOG

Contact

Kim Turner, R.N. at 563-421-1908
or turnerk@genesishealth.com